Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer

Gynecologic Oncology

Volumn 141, Issue 3, 2016, Pages 405-409

  Alvarez, Ronald D ^a   Matulonis, Ursula A ^b   Herzog, Thomas J ^c   Coleman, Robert L ^d   Monk, Bradley J ^e   Markman, Maurie ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Platinum sensitive resistant; Recurrent ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; PLATINUM; PLATINUM COMPLEX;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL DECISION MAKING; DIAGNOSTIC IMAGING; DRUG SENSITIVITY; EDITORIAL; GENE MUTATION; HUMAN; LONG TERM SURVIVAL; MOLECULAR BIOLOGY; OVARY CANCER; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMBINATION REPAIR; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; DRUG RESISTANCE; FEMALE; OVARY TUMOR; TUMOR RECURRENCE;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84975217483     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.03.005     Document Type: Editorial

References (27)

1. Markman, M., Rothman, R., Hakes, T., Reichmann, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., Lewis, J.L., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991), 389–393.
2. Blackledge, G., Lawton, F., Redman, C., Kelly, K., Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br. J. Cancer 59:4 (1989), 650–653.
3. Gore, M.E., Fryatt, I., Wiltshaw, E., Dawson, T., Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36:2 (1990), 207–211.
4. Salani, R., Backes, F.J., Fung, M.F., Holschneider, C.H., Parker, L.P., Bristow, R.E., Goff, B.A., Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am. J. Obstet. Gynecol. 204:6 (2011), 466–478.
5. Morgan, R.J. Jr., Alvarez, R.D., Armstrong, D.K., Burger, R.A., Chen, L.M., Copeland, L., Crispens, M.A., Gershenson, D.M., Gray, H.J., Hakam, A., Havrilesky, L.J., Johnston, C., Lele, S., Martin, L., Matulonis, U.A., O'Malley, D.M., Penson, R.T., Powell, M.A., Remmenga, S.W., Sabbatini, P., Santoso, J.T., Schink, J.C., Teng, N., Werner, T.L., Dwyer, M.A., Hughes, M., National comprehensive cancer networks. Ovarian cancer, version 2.2013. J. Natl. Compr. Cancer Netw. 11:10 (2013), 1199–1209.
6. Rustin, G.J., van der Burg, M.E., Griffin, C.L., Guthrie, D., Lamont, A., Jayson, G.C., Kristensen, G., Mediola, C., Coens, C., Qian, W., Parmar, M.K., Swart AM; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:9747 (2010 Oct 2), 1155–1163.
7. Bilici, A., Ustaalioglu, B.B.O., Seker, M., Canpolat, N., Tekinsoy, B., Salepci, T., Gumau, M., Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 1259–1269.
8. Wilder, J.L., Pavlik, E., Straughn, J.M., Kirby, T., Higgins, R.V., DePriest, P.D., Ueland, F.R., Kryscio, R.J., Whitley, R.J., van Nagell, J., Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol. Oncol. 89:2 (2003), 233–235.
9. Bhosale, P., Peungjesada, S., Wei, W., Levenback, C.F., Schmeler, K., Rohren, E., Macapinlac, H.A., Iyer, R.B., Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int. J. Gynecol. Cancer 20:6 (2010), 936–944.
10. Rustin, G.J., Maples, M., Nelstrop, A.E., Mahmoudi, M., Meyer, T., Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19 (2001), 4054–4057.
11. Parmar, M.K., Ledermann, J.A., Colombo, N., du Bois, A., Delaloye, J.F., Kristensen, G.B., Wheeler, S., Swart, A.M., Qian, W., Torri, V., Floriani, I., Jayson, G., Lamont, A., Tropé, C., ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:9375 (2003), 2099–2106.
12. Kavanagh, J., Tresukosol, D., Edwards, C., Freedman, R., Gonzales de Leon, C., Fishman, A., Mante, R., Hord, M., Kudleka, A., Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13 (1995), 1584–1588.
13. Leitao, M.M., Hummer, A., Dizon, D.S., Aghajanian, C., Hensley, M., Sabbatini, P., Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol. Oncol. 91 (2003), 123–129.
14. Groen, R.S., Gershenson, D.M., Fader, A.N., Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol. Oncol. 136:2 (2015), 373–383.
15. Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A.K., Zhang, W., Association of BRCA 1 and BRCA 2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:14 (2011), 1557–1565.
16. Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., Belinson, J., Continued chemosensititivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol. Oncol. 65 (1997), 434–436.
17. Alsop, K., Fereday, S., Meldrum, C., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M.J., Webb, P.M., Stewart, C., Friedlander, M., Fox, S., Bowtwell, D., Mitchell, G., BRCA mutation frequency and patterns of response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30 (2012), 2654–2663.
18. Safra, T., Borgato, L., Nicolletto, M.O., Rolnitzky, L., Pelles-Avraham, S., Geva, R., Donach, M.E., Curtin, J., Novetsky, A., Grenader, T., Lai, W.-C.V., Gabizon, A., Boyd, L., Muggia, F., Mol. Cancer Ther. 10:10 (2011), 2000–2007.
19. Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., Amnon, A., Bell-McGuinn, K.M., Chen, L.M., Friedlander, M., Safra, T., Vergote, I., Wickens, M., Lowe, E.S., Carmichael, J., Kaufman, B., Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30:4 (2012), 372–379 (1).
20. Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., Audeh, M.W., Friedlander, M., Balmana, J., Mitchell, G., Fried, G., Temmern, S.M., Hubert, A., Rosengarten, O., Stiener, M., Loman, N., Bowen, K., Fielding, A., Domchek, S.M., Olaparib monotherapy in patients with advanced cancer and a germline BRCA 1/2 mutation. J. Clin. Oncol. 33:3 (2015), 244–250.
21. Norquist, B., Wurz, K.A., Pennil, C.C., Garcia, R., Gross, J., Sakai, W., Karlan, B.Y., Taniguchi, T., Swisher, W.M., Secondary somatic mutations restoring BRCA 1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29:22 (2011), 3008–3015.
22. The Cancer Genome Atlas Research Network, Integrated genomic analysis of ovarian carcinoma. Nature 474 (2011), 609–615.
23. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C.L., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Fielding, A., Spencer, S., Dougherty, B., Orr, M., Hodgson, D., Barrett, J.C., Matulonis, U., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:8 (2014), 852–861.
24. McNeish IA, Oza AM, Coleman RL, Scott CL, Konecny GE, Tinker A, O'Malley DM, Brenton J, Kristeleit RS, Bell-McGuinn K, Oaknin A, Leary A, Lin K, Raponi M, Giordano H, Goble S, Rolfe L, Yelensky R, Allen AR, Swisher EM. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. ASCO 2015 Annual Meeting.
25. Nelson, B.H., New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr. Opin. Immunol. 33 (2015), 93–100.
26. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., Matsumura, N., Abiko, K., Baba, T., Yamaguchi, K., Ueda, A., Hosoe, Y., Morita, S., Yokode, M., Shimizu, A., Honjo, T., Konishi, I., Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33:34 (2015), 4015–4022.
27. Galon, J., Mlecnik, B., Bindea, G., HK, Angell, Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., Nagtegaal, I.D., Palmqvist, R., Masucci, G.V., Botti, G., Tatangelo, F., Delrio, P., Maio, M., Laghi, L., Grizzi, F., Asslaber, M., D'Arrigo, C., Vidal-Vanaclocha, F., Zavadova, E., Chouchane, L., Ohashi, P.S., Hafezi-Bakhtiari, S., Wouters, B.G., Roehrl, M., Nguyen, L., Kawakami, Y., Hazama, S., Okuno, K., Ogino, S., Gibbs, P., Waring, P., Sato, N., Torigoe, T., Itoh, K., Patel, P.S., Shukla, S.N., Wang, Y., Kopetz, S., Sinicropem, F.A., Scripcariu, V., Ascierto, P.A., Marincola, F.M., Fox, B.A., Pagès, F., Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232:2 (2014), 199–209.